Project Grant R01AI181944
Award Date
8/1/25
Completion Date
7/31/29
Dollars Obligated
$3.2M
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
This Project Grant award, valued at $792,687.00 and issued by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to define the structural features of sialoglycans necessary for influenza A virus (IAV) infection and adaptation across various host species. The key activities under this award include: 1) using CRISPR/Cas9 techniques to truncate different types of sialoglycans in human lung...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $3,085,097.00 to the University of Wisconsin - Madison to study the role of cryptic influenza virus proteins in viral replication and pathogenesis. The research aims to characterize the interference activity and mechanism of action of these previously unknown viral proteins, define the full repertoire of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $722,958 to the University of Rochester to investigate the role of monocyte-derived galectin-1 in promoting tissue-resident memory T cell responses against influenza virus. The research aims to (1) study monocyte differentiation during immune memory formation after influenza infection, (2) determine how galectin-1...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $230,000 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the Scripps Research Institute. The purpose of this 2-year grant, with a start date of January 23, 2025, is to evaluate recently discovered neuraminidase broadly neutralizing antibodies (NA BnAbs) for their potential use in a universal influenza vaccine. The research will assess factors such as precursor frequency,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $143,450 to support research on developing therapies for treating viral-induced acute lung injury. The primary focus is on evaluating the therapeutic efficacy of combinations of PPARG agonist and RXR ligand compounds in cotton rat models of influenza and respiratory syncytial virus (RSV) infection. The research...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $605,778 to The Ohio State University to elucidate how influenza A viruses (IAV) manipulate the cellular protein ARIH2 to promote viral replication in airway epithelial cells. The research aims to uncover ARIH2 as a novel IAV restriction factor exploited by the virus, and evaluate ARIH2's potential as a therapeutic...
This Project Grant award of $438,500.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of California, San Diego (UCSD). The primary objectives of this research project are to: Identify the sequence interface regulating interactions between the influenza A virus (IAV) protein NS2 and the viral polymerase, using a high-throughput mutation approach. Explore preliminary...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $433,125 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The funding supports research to investigate the role of the influenza A virus (IAV) protein PB1-F2 in causing hypoxemia (low blood oxygen levels) and acute respiratory distress syndrome (ARDS) in influenza infections. The research aims to define the effects of PB1-F2 on alveolar type II (ATII)...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under CFDA Program 93.855 - Allergy and Infectious Diseases Research, is providing $146,922.00 to Emory University to conduct research on factors that modulate the efficiency of influenza A virus (IAV) infection. The research aims to examine the relationship between the intensity of IAV exposure and infection diversity under distinct modes of exposure (intranasal vs. aerosol). Additionally, the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) provides $254,250 to New York University (NYU) from July 1, 2025 to June 30, 2027. The funding supports research to understand how pathogenic alphaviruses, such as chikungunya virus, infect and spread through human microvascular endothelial cells. The research aims to identify viral and host factors that restrict alphavirus...